Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Head and Neck Neoplasms 6Neoplasms 5Carcinoma, Squamous Cell 4Sarcoma, Kaposi 3Hodgkin Disease 3HIV Infections 3Acquired Immunodeficiency Syndrome 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma 2Carcinoma 2Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Laryngeal Diseases 1Hematologic Diseases 1Breast Neoplasms 1

Interventions

Dexamethasone 64Lenalidomide 34pomalidomide 33Cyclophosphamide 33Rituximab 31Bortezomib 29venetoclax 27fludarabine 26Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 16Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Injections 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Bleomycin × Clear all
NCT01606566 2022-02-18

A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck Cancer.

PCI Biotech AS

Phase 2 Terminated
26 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡